| ARDELYX INC. DL-,0001 |
| USA |
| Gesundheit |
| US0396971071 / A116X0 |
| 41X (Frankfurt) / ARDX (NASDAQ) |
| FRA:41X, ETR:41X, 41X:GR, NASDAQ:ARDX |
| - |
| https://ardelyx.com/ |
|
Ardelyx Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of gastrointestinal (GI) and related disorders. The company'..
>Volltext.. |
| 1192.45 Mio. EUR |
| 1144.2 Mio. EUR |
| 345.63 Mio. EUR |
| -32.18 Mio. EUR |
| -52.27 Mio. EUR |
| -0.22 EUR |
| 176.46 Mio. EUR |
| 57.7 Mio. EUR |
| -36.05 Mio. EUR |
| 2.99 |
| 7.61% |
| -38.73% |
| - |
| - |
| - |
| ARDELYX |
| 24.02.26 |
|